Company intelligence / Profile preview
Myricx Bio
London, United Kingdom
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Myricx has demonstrated complete tumor regressions across multiple solid tumor xenograft models for NMTi-ADCs targeting three clinically validated tumor-associated antigens (B7-H3, TROP2 and HER2) with encouraging initial non-human primate tolerability data. The company has shown that NMTi ADCs achieve complete and durable tumor regressions at well tolerated doses in multiple solid cancer models that are refractory to topoisomerase inhibitor-based ADCs.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
WuXi BiologicsBiocytogen Pharmaceuticals
Beyond the preview
Go deeper on Myricx Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Myricx Bio.